Ultragenyx Pharmaceutical (RARE) Competitors $28.40 -1.07 (-3.63%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$29.04 +0.64 (+2.25%) As of 09/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. QGEN, BBIO, ROIV, MRNA, ELAN, VRNA, RVMD, GRFS, ABVX, and RYTMShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), Abivax (ABVX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Its Competitors QIAGEN BridgeBio Pharma Roivant Sciences Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Grifols Abivax Rhythm Pharmaceuticals QIAGEN (NYSE:QGEN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Do analysts rate QGEN or RARE? QIAGEN currently has a consensus target price of $49.69, suggesting a potential upside of 8.95%. Ultragenyx Pharmaceutical has a consensus target price of $81.50, suggesting a potential upside of 186.97%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than QIAGEN.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QIAGEN 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has more volatility & risk, QGEN or RARE? QIAGEN has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Does the media favor QGEN or RARE? In the previous week, QIAGEN and QIAGEN both had 7 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 0.99 beat QIAGEN's score of 0.91 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QIAGEN 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, QGEN or RARE? QIAGEN has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQIAGEN$1.98B5.12$83.59M$1.6926.98Ultragenyx Pharmaceutical$560.23M4.89-$569.18M-$5.53-5.14 Do insiders & institutionals hold more shares of QGEN or RARE? 70.0% of QIAGEN shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is QGEN or RARE more profitable? QIAGEN has a net margin of 18.30% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. QIAGEN's return on equity of 14.77% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets QIAGEN18.30% 14.77% 8.87% Ultragenyx Pharmaceutical -87.34%-237.48%-37.66% SummaryQIAGEN beats Ultragenyx Pharmaceutical on 10 of the 15 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84B$3.16B$5.76B$10.51BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-5.1421.0476.4326.62Price / Sales4.89252.12473.3192.90Price / CashN/A46.3537.4661.85Price / Book10.299.7813.616.45Net Income-$569.18M-$52.73M$3.29B$271.57M7 Day Performance-1.08%3.16%1.87%2.61%1 Month Performance-4.63%4.69%4.03%7.28%1 Year Performance-50.59%16.37%77.41%29.60% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.3883 of 5 stars$28.40-3.6%$81.50+187.0%-50.7%$2.84B$560.23M-5.141,294Positive NewsQGENQIAGEN4.3622 of 5 stars$45.39+0.2%$49.69+9.5%+5.5%$10.09B$1.98B26.825,765BBIOBridgeBio Pharma4.4951 of 5 stars$51.47+0.5%$63.94+24.2%+102.8%$9.84B$221.90M-12.58400ROIVRoivant Sciences3.4223 of 5 stars$13.95-0.9%$17.67+26.6%+23.9%$9.53B$29.05M-19.93860Trending NewsInsider TradeAnalyst RevisionMRNAModerna4.4574 of 5 stars$23.88+1.6%$41.81+75.1%-59.8%$9.29B$3.24B-3.175,800Trending NewsELANElanco Animal Health2.5844 of 5 stars$18.63+0.5%$17.33-6.9%+28.5%$9.25B$4.44B21.669,000Positive NewsVRNAVerona Pharma PLC American Depositary Share2.0305 of 5 stars$106.37-0.1%$109.00+2.5%+259.0%$9.17B$42.28M-107.4430Positive NewsRVMDRevolution Medicines4.2884 of 5 stars$46.20-0.8%$73.67+59.5%+3.7%$8.64B$11.58M-10.27250GRFSGrifols3.9122 of 5 stars$9.63-2.5%$10.30+7.0%+11.9%$6.62B$7.45B8.2323,822Positive NewsABVXAbivax2.7984 of 5 stars$85.87+2.2%$99.43+15.8%+655.2%$6.49BN/A0.0061RYTMRhythm Pharmaceuticals3.2028 of 5 stars$96.03-0.2%$101.57+5.8%+93.3%$6.38B$130.13M-31.90140Positive News Related Companies and Tools Related Companies QIAGEN Alternatives BridgeBio Pharma Alternatives Roivant Sciences Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Grifols Alternatives Abivax Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
